The University of Chicago Header Logo

Arlene Chapman

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
Phone+1 (773) 795-1376
Email
vCardDownload vCard

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    R21AT004509     (RAHBARI-OSKOUI, FREDERIC FARID)Jul 1, 2009 - Jun 30, 2014
    NIH
    Melatonin and Nighttime Blood Pressure in African Americans
    Role: Co-Principal Investigator
    R13DK063908     (CHAPMAN, ARLENE B)Sep 1, 2002 - Aug 31, 2003
    NIH
    Symposium for Molecular and Therapeutic Insights in PKD
    Role: Principal Investigator
    U01DK062408     (RAHBARI-OSKOUI, FREDERIC FARID)Aug 15, 2002 - Jan 31, 2016
    NIH
    Limited Competition: Clinical Centers for the HALT-Polycystic Kidney Disease Tria
    Role: Co-Principal Investigator
    U01DK056956     (CHAPMAN, ARLENE B.)Feb 1, 2000 - Nov 30, 2017
    NIH
    Limited Competition for the Continuation of the Consortium for Radiologic Imaging
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chekka LMS, Tantawy M, Langaee T, Wang D, Renne R, Chapman AB, Gums JG, Boerwinkle E, Cooper-DeHoff RM, Johnson JA. Circulating microRNA Biomarkers of Thiazide Response in Hypertension. J Am Heart Assoc. 2024 Feb 20; 13(4):e032433. PMID: 38353215.
      Citations:    Fields:    Translation:Humans
    2. Elliott B, Márquez-Nogueras KM, Thuo P, DiNello E, Knutila RM, Fritzmann GE, Willis M, Chapman AB, Cao Q, Barefield DY, Kuo IY. Cardiac Localized Polycystin-2 plays a Functional Role in Natriuretic Peptide Production and its Absence Contributes to Hypertension. bioRxiv. 2024 Jan 02. PMID: 38260706; PMCID: PMC10802350.
      Citations:    
    3. Kremer LE, Chapman AB, Armato SG. Magnetic resonance imaging preprocessing and radiomic features for classification of autosomal dominant polycystic kidney disease genotype. J Med Imaging (Bellingham). 2023 Nov; 10(6):064503. PMID: 38156331; PMCID: PMC10752557.
      Citations:    
    4. Chapman AB. All Patients with ADPKD Should Undergo Screening for Intracranial Aneurysms: COMMENTARY. Kidney360. 2023 Nov 22. PMID: 37990357.
      Citations:    Fields:    
    5. Al Sayyab M, Chapman A. Pregnancy in Autosomal Dominant Polycystic Kidney Disease. Adv Kidney Dis Health. 2023 Sep; 30(5):454-460. PMID: 38032583.
      Citations:    Translation:Humans
    6. Perrone RD, Oberdhan D, Ouyang J, Chapman AB, Gitomer BY, Horie S, Ong ACM, Torres VE, Turner AN, Krasa H, Bichet DG, Budde K. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney Int Rep. 2023 May; 8(5):989-1001. PMID: 37180499; PMCID: PMC10166786.
      Citations: 3     
    7. Gregory AV, Chebib FT, Poudyal B, Holmes HL, Yu ASL, Landsittel DP, Bae KT, Chapman AB, Frederic RO, Mrug M, Bennett WM, Harris PC, Erickson BJ, Torres VE, Kline TL. Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation. Kidney Int. 2023 08; 104(2):334-342. PMID: 36736536; PMCID: PMC10363210.
      Citations: 5     Fields:    Translation:Humans
    8. Gansevoort RT, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, Mrug M, Ong ACM, Pei YPC, Torres VE, Modur V, Antonshchuk I, Perrone RD, Knebelmann B. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Am J Kidney Dis. 2023 05; 81(5):517-527.e1. PMID: 36535535.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    9. Lobo R, Lieske JC, Donato LJ, Hickson LJ, Hodge DO, Chapman A, Schwartz GL, Jaffe AS. Measuring Copeptin, a surrogate for Vasopressin in Patients with Hypertension - Can it identify those who are Volume Responsive? Clin Biochem. 2022 Dec 02. PMID: 36470342.
      Citations: 1     Fields:    
    10. Pergola PE, Agarwal R, Andreoli S, Appel GB, Bangalore S, Block GA, Chapman AB, Chin MP, Gibson KL, Goldsberry A, Iijima K, Inker LA, Kashtan CE, Mariani LH, Meyer CJ, Nozu K, O'Grady M, Rheault MN, Silva AL, Stenvinkel P, Torra R, Chertow GM, Warady BA, Knebelmann B. Effects of Bardoxolone Methyl in Alport Syndrome. Clin J Am Soc Nephrol. 2022 12; 17(12):1763-1774. PMID: 36411058; PMCID: PMC9718021.
      Citations: 8     Fields:    Translation:Humans
    11. Chekka LMS, Cooper-DeHoff RM, Gums JG, Chapman AB, Johnson JA. Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients. Clin Transl Sci. 2022 Oct 21. PMID: 36271676.
      Citations:    Fields:    
    12. Perrone RD, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, Mrug M, Ong ACM, Pei YPC, Torres VE, Modur V, Gansevoort RT, Knebelmann B. The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD. Kidney Med. 2022 Oct; 4(10):100538. PMID: 36204243; PMCID: PMC9529969.
      Citations:    
    13. Mehanna M, McDonough CW, Smith SM, Gong Y, Gums JG, Chapman AB, Johnson JA, Cooper-DeHoff RM. Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients. Metabolites. 2022 Aug 24; 12(9). PMID: 36144188; PMCID: PMC9506508.
      Citations: 1     
    14. Torres J, Ennis JL, Chapman AB, McGill RL. Utilization of Cystatin C in the Outpatient Setting. Am J Nephrol. 2022; 53(7):534-541. PMID: 35738242.
      Citations: 1     Fields:    Translation:Humans
    15. Saunders MR, Hayward AL, Chapman AB, McGill RL. Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022 07; 17(7):976-985. PMID: 35725555; PMCID: PMC9269641.
      Citations: 1     Fields:    Translation:Humans
    16. Tao C, Feldman R, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Mrug M, Bennett WM, Harris PC, Srivastava A, Landsittel DP, Abebe KZ, CRISP and HALT PKD Consortium, Bae KT. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):374-384. PMID: 35217526; PMCID: PMC8975034.
      Citations: 1     Fields:    Translation:Humans
    17. Eadon MT, Maddatu J, Moe SM, Sinha AD, Ferreira RM, Miller BW, Sher SJ, Su J, Pratt VM, Chapman AB, Skaar TC, Moorthi RN. Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360. 2022 02; 3(2):307-316. PMID: 35342886; PMCID: PMC8953763.
      Citations: 6     Fields:    Translation:Humans
    18. Devarajan P, Chertow GM, Susztak K, Levin A, Agarwal R, Stenvinkel P, Chapman AB, Warady BA. Emerging Role of Clinical Genetics in CKD. Kidney Med. 2022 Apr; 4(4):100435. PMID: 35372818; PMCID: PMC8971313.
      Citations: 7     
    19. Chapman AB, McGill R. Polycystic Kidney Disease in the Real World. Kidney360. 2021 12 30; 2(12):1882-1883. PMID: 35419534; PMCID: PMC8986036.
      Citations:    Fields:    Translation:Humans
    20. Steele C, You Z, Gitomer BY, Brosnahan GM, Abebe KZ, Braun WE, Chapman AB, Harris PC, Perrone RD, Steinman TI, Torres VE, Yu ASL, Chonchol M, Nowak KL. PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney Int Rep. 2022 Jan; 7(1):117-120. PMID: 35005320; PMCID: PMC8720657.
      Citations:    
    21. Mehanna M, McDonough CW, Smith SM, Gong Y, Gums JG, Chapman AB, Johnson JA, McIntyre L, Cooper-DeHoff RM. Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. Metabolites. 2021 Sep 21; 11(9). PMID: 34564461; PMCID: PMC8466669.
      Citations: 4     
    22. Betz MV, Coe FL, Chapman AB. Agreement of Food Records and 24-Hour Urine Studies in Clinical Practice. J Ren Nutr. 2022 01; 32(1):51-57. PMID: 34429244.
      Citations: 1     Fields:    Translation:Humans
    23. Natale P, Perrone RD, Tong A, Harris T, Hannan E, Ju A, Burnette E, Casteleijn NF, Chapman A, Eastty S, Gansevoort RT, Hogan M, Horie S, Lee R, Mustafa RA, Sandford R, Baumgart A, Craig JC, Rangan GK, Viecelli AK, Amir N, Evangelidis N, Guha C, Logeman C, Manera K, Matus Gonzalez A, Howell M, Strippoli GFM, Cho Y, Knebelmann B, Sautenet B. Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. Clin Kidney J. 2022 Mar; 15(3):407-416. PMID: 35211300; PMCID: PMC8862067.
      Citations: 2     
    24. Torres VE, Gansevoort RT, Perrone RD, Chapman AB, Ouyang J, Lee J, Japes H, Nourbakhsh A, Wang T. Tolvaptan in ADPKD Patients With Very Low Kidney Function. Kidney Int Rep. 2021 Aug; 6(8):2171-2178. PMID: 34386666; PMCID: PMC8343715.
      Citations: 9     
    25. Natale P, Hannan E, Ju A, Perrone RD, Burnette E, Casteleijn N, Chapman A, Eastty S, Gansevoort R, Hogan M, Horie S, Lee R, Mustafa RA, Sandford R, Baumgart A, Tong A, Strippoli GFM, Craig JC, Rangan GK, Cho Y, Sautenet B, Knebelmann B. Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS One. 2021; 16(5):e0252479. PMID: 34043715; PMCID: PMC8158964.
      Citations: 2     Fields:    Translation:Humans
    26. Nowak KL, Murray K, You Z, Gitomer B, Brosnahan G, Abebe KZ, Braun W, Chapman A, Harris PC, Miskulin D, Perrone R, Torres V, Steinman T, Yu A, Chonchol M. Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Med. 2021 Jul-Aug; 3(4):536-545.e1. PMID: 34401721; PMCID: PMC8350824.
      Citations: 5     
    27. Heida JE, Gansevoort RT, Torres VE, Devuyst O, Perrone RD, Lee J, Li H, Ouyang J, Chapman AB. The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial. J Am Soc Nephrol. 2021 Jul; 32(7):1801-1812. PMID: 33888577; PMCID: PMC8425647.
      Citations: 2     Fields:    
    28. Chertow GM, Appel GB, Andreoli S, Bangalore S, Block GA, Chapman AB, Chin MP, Gibson KL, Goldsberry A, Iijima K, Inker LA, Mariani LH, Meyer CJ, Nozu K, O'Grady M, Silva AL, Stenvinkel P, Torra R, Warady BA, Pergola PE, Knebelmann B. Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. Am J Nephrol. 2021; 52(3):180-189. PMID: 33789284; PMCID: PMC8220919.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    29. Prochaska M, Asplin J, Chapman A, Worcester E. Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass. Am J Nephrol. 2021; 52(2):173-176. PMID: 33765680; PMCID: PMC8049982.
      Citations:    Fields:    Translation:Humans
    30. El Ters M, Lu P, Mahnken JD, Stubbs JR, Zhang S, Wallace DP, Grantham JJ, Chapman AB, Torres VE, Harris PC, Bae KT, Landsittel DP, Rahbari-Oskoui FF, Mrug M, Bennett WM, Yu ASL. Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2021 Apr; 6(4):953-961. PMID: 33912745; PMCID: PMC8071629.
      Citations: 5     
    31. Chekka LMS, Chapman AB, Gums JG, Cooper-DeHoff RM, Johnson JA. Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. Am J Med. 2021 07; 134(7):918-925.e2. PMID: 33434556; PMCID: PMC8243781.
      Citations:    Fields:    Translation:Humans
    32. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020 12 31; 16(1):48-58. PMID: 33376102; PMCID: PMC7792652.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    33. Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee TY, Gong Y, Wang D, Schmidt SO, Binkley PF, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman AB, Cooper-DeHoff RM, Gums JG, Hamadeh IS, Zhao L, Schmidt S, Frye RF, Johnson JA, Cavallari LH. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. CPT Pharmacometrics Syst Pharmacol. 2020 12; 9(12):678-685. PMID: 33067866; PMCID: PMC7762806.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    34. Logeman C, Cho Y, Rangan GK, Gutman T, Craig J, Ong A, Chapman A, Ahn C, Coolican H, Tze-Wah Kao J, Gansevoort RT, Perrone R, Harris T, Torres V, Fowler K, Pei Y, Kerr P, Ryan J, Johnson D, Viecelli A, Kim H, Kim Y, Howell M, Ju A, Manera KE, Teixeira-Pinto A, Parasivam G, Tong A, Sautenet B, Geneste C. 'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open. 2020 10 10; 10(10):e038005. PMID: 33040007; PMCID: PMC7549480.
      Citations: 3     Fields:    Translation:Humans
    35. Gitomer B, Pereira R, Salusky IB, Stoneback JW, Isakova T, Cai X, Dalrymple LS, Ofsthun N, You Z, Malluche HH, Maddux F, George D, Torres V, Chapman A, Steinman TI, Wolf M, Chonchol M. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2021 04; 99(4):977-985. PMID: 32926884; PMCID: PMC7993988.
      Citations: 8     Fields:    Translation:HumansAnimals
    36. Braden GL, Chapman A, Ellison DH, Gadegbeku CA, Gurley SB, Igarashi P, Kelepouris E, Moxey-Mims MM, Okusa MD, Plumb TJ, Quaggin SE, Salant DJ, Segal MS, Shankland SJ, Somlo S. Advancing Nephrology: Division Leaders Advise ASN. Clin J Am Soc Nephrol. 2021 02 08; 16(2):319-327. PMID: 32792352; PMCID: PMC7863658.
      Citations: 3     Fields:    Translation:Humans
    37. Lavu S, Vaughan LE, Senum SR, Kline TL, Chapman AB, Perrone RD, Mrug M, Braun WE, Steinman TI, Rahbari-Oskoui FF, Brosnahan GM, Bae KT, Landsittel D, Chebib FT, Yu AS, Torres VE, HALT PKD and CRISP Study Investigators, Harris PC. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15). PMID: 32634120; PMCID: PMC7455088.
      Citations: 21     Fields:    Translation:Humans
    38. Cho Y, Tong A, Craig JC, Mustafa RA, Chapman A, Perrone RD, Ahn C, Fowler K, Torres V, Gansevoort RT, Ong ACM, Coolican H, Tze-Wah Kao J, Harris T, Gutman T, Shen JI, Viecelli AK, Johnson DW, Au E, El-Damanawi R, Logeman C, Ju A, Manera KE, Chonchol M, Odland D, Baron D, Pei Y, Sautenet B, Rastogi A, Sharma A, Rangan G, SONG-PKD Workshop Investigators. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. Am J Kidney Dis. 2021 02; 77(2):255-263. PMID: 32771648.
      Citations: 18     Fields:    Translation:Humans
    39. Grau L, Gitomer B, McNair B, Wolf M, Harris P, Brosnahan G, Torres V, Steinman T, Yu A, Chapman A, Chonchol M, Nowak KL. Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2020 Jul; 1(7):648-656. PMID: 33305291; PMCID: PMC7725226.
      Citations: 3     Fields:    Translation:Humans
    40. Bae KT, Shi T, Tao C, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Srivastava A, Irazabal MV, Abebe KZ, Harris PC, Landsittel DP, HALT PKD Consortium. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 07; 31(7):1640-1651. PMID: 32487558; PMCID: PMC7350997.
      Citations: 11     Fields:    Translation:Humans
    41. Cho Y, Rangan G, Logeman C, Ryu H, Sautenet B, Perrone RD, Nadeau-Fredette AC, Mustafa RA, Htay H, Chonchol M, Harris T, Gutman T, Craig JC, Ong ACM, Chapman A, Ahn C, Coolican H, Kao JT, Gansevoort RT, Torres V, Pei Y, Johnson DW, Viecelli AK, Teixeira-Pinto A, Howell M, Ju A, Manera KE, Tong A. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. Am J Kidney Dis. 2020 09; 76(3):361-373. PMID: 32359822.
      Citations: 10     Fields:    Translation:Humans
    42. Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, Shoaf SE. The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney Int Rep. 2020 Jun; 5(6):801-812. PMID: 32518862; PMCID: PMC7271939.
      Citations: 12     
    43. Yang J, Asico LD, Beitelshees AL, Feranil JB, Wang X, Jones JE, Armando I, Cuevas SG, Schwartz GL, Gums JG, Chapman AB, Turner ST, Boerwinkle E, Cooper-DeHoff RM, Johnson JA, Felder RA, Weinman EJ, Zeng C, Jose PA, Villar VAM. Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB J. 2020 06; 34(6):7941-7957. PMID: 32293069; PMCID: PMC7643053.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    44. Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, Shoaf SE. A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. Kidney Int Rep. 2020 Jun; 5(6):790-800. PMID: 32518861; PMCID: PMC7271942.
      Citations: 5     
    45. Cho Y, Gutman T, Rangan G, Ong A, Chapman AB, Ahn C, Coolican H, Tze-Wah Kao J, Fowler K, Gansevoort RT, Perrone RD, Harris T, Torres VE, Pei Y, Craig JC, Tong A, SONG-PKD Initiative, Sautenet B, Geneste C. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. Am J Kidney Dis. 2020 08; 76(2):213-223. PMID: 32171640.
      Citations: 11     Fields:    Translation:Humans
    46. Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, Cooper-Dehoff RM. Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. Am J Hypertens. 2020 02 22; 33(2):e2. PMID: 31891170.
      Citations:    Fields:    Translation:Humans
    47. Kuo IY, Chapman AB. Polycystins, ADPKD, and Cardiovascular Disease. Kidney Int Rep. 2020 Apr; 5(4):396-406. PMID: 32274448; PMCID: PMC7136326.
      Citations: 20     
    48. Patel A, Chapman AB, Mikolajczyk AE. A Practical Approach to Polycystic Liver Disease. Clin Liver Dis (Hoboken). 2019 Nov; 14(5):176-179. PMID: 31879559; PMCID: PMC6924961.
      Citations: 4     
    49. Singh S, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 11 21; 9(1):17323. PMID: 31754133; PMCID: PMC6872535.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    50. Hopp K, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui FF, Torres VE, HALT Progression of Polycystic Kidney Disease Group, the ADPKD Modifier Study, Harris PC, Cornec-Le Gall E. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 02; 97(2):370-382. PMID: 31874800; PMCID: PMC7218796.
      Citations: 24     Fields:    Translation:Humans
    51. Cunningham PN, Wang Z, Grove ML, Cooper-DeHoff RM, Beitelshees AL, Gong Y, Gums JG, Johnson JA, Turner ST, Boerwinkle E, Chapman AB. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957. PMID: 31532792; PMCID: PMC6750571.
      Citations: 3     Fields:    Translation:Humans
    52. Hanudel MR, Salusky IB, Pereira RC, Wang W, You Z, Nowak KL, Brosnahan GM, Torres VE, Chapman AB, Perrone RD, Steinman TI, Bae KT, Gitomer BY, Chonchol MB. Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney Int Rep. 2019 Dec; 4(12):1742-1748. PMID: 31844811; PMCID: PMC6895647.
      Citations: 3     
    53. Singh S, Warren HR, Hiltunen TP, McDonough CW, El Rouby N, Salvi E, Wang Z, Garofalidou T, Fyhrquist F, Kontula KK, Glorioso V, Zaninello R, Glorioso N, Pepine CJ, Munroe PB, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, Gong Y, Cooper-DeHoff RM. Genome-Wide Meta-Analysis of Blood Pressure Response to ß1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115. PMID: 31423876; PMCID: PMC6759913.
      Citations: 15     Fields:    Translation:Humans
    54. Kuo IY, Chapman A. Intracranial Aneurysms in ADPKD: How Far Have We Come? Clin J Am Soc Nephrol. 2019 Aug 01; 14(8):1119-1121. PMID: 37128121; PMCID: PMC6682827.
      Citations: 4     Fields:    
    55. Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, Cooper-DeHoff RM. Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. Am J Hypertens. 2019 06 11; 32(7):668-675. PMID: 30753254; PMCID: PMC6558666.
      Citations: 5     Fields:    Translation:Humans
    56. Singh S, El Rouby N, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans. Clin Transl Sci. 2019 09; 12(5):497-504. PMID: 31033190; PMCID: PMC6742943.
      Citations: 7     Fields:    Translation:Humans
    57. Zhou W, Shen C, Landsittel DP, Wu Z, Tao C, Chapman AB, Torres VE, Yu ASL, Mrug M, Bennett WM, Harris PC, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP), Bae KT. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 06 07; 14(6):823-833. PMID: 31088850; PMCID: PMC6556721.
      Citations: 15     Fields:    Translation:Humans
    58. Shahin MH, Rouby NE, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. ß2 -Adrenergic Receptor Gene Affects the Heart Rate Response of ß-Blockers: Evidence From 3 Clinical Studies. J Clin Pharmacol. 2019 11; 59(11):1462-1470. PMID: 31090079; PMCID: PMC6773496.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    59. Cho Y, Sautenet B, Gutman T, Rangan G, Craig JC, Ong AC, Chapman A, Ahn C, Coolican H, Kao JT, Gansevoort R, Perrone RD, Harris T, Torres V, Pei Y, Kerr PG, Ryan J, Johnson DW, Viecelli AK, Geneste C, Kim H, Kim Y, Oh YK, Teixeira-Pinto A, Logeman C, Howell M, Ju A, Manera KE, Tong A. Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology (Carlton). 2019 Dec; 24(12):1214-1224. PMID: 30663163.
      Citations: 10     Fields:    Translation:Humans
    60. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, TEMPO 3:4 Investigators, Devuyst O. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169. PMID: 30898339; PMCID: PMC6640141.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    61. Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, Chapman AB, Bae KT, Mrug M, Harris PC, Rahbari-Oskoui FF, Shi T, Bennett WM, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019 05; 95(5):1253-1261. PMID: 30922668; PMCID: PMC6478515.
      Citations: 32     Fields:    Translation:Humans
    62. Cunningham PN, Chapman AB. The future of pharmacogenetics in the treatment of hypertension. Pharmacogenomics. 2019 02; 20(3):129-132. PMID: 30808251.
      Citations: 6     Fields:    Translation:Humans
    63. Kim K, Trott JF, Gao G, Chapman A, Weiss RH. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 2019 02 25; 20(1):66. PMID: 30803434; PMCID: PMC6388487.
      Citations: 10     Fields:    Translation:Humans
    64. Solayman MH, Langaee TY, Gong Y, Shahin MH, Turner ST, Chapman AB, Gums JG, Boerwinkle E, Beitelshees AL, El-Hamamsy M, El-Wakeel L, Cooper-DeHoff RM, Badary OA, Johnson JA. Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. Eur J Pharm Sci. 2019 Apr 01; 131:93-98. PMID: 30753892; PMCID: PMC6467266.
      Citations: 8     Fields:    Translation:Humans
    65. Collins KS, Pratt VM, Stansberry WM, Medeiros EB, Kannegolla K, Swart M, Skaar TC, Chapman AB, Decker BS, Moorthi RN, Eadon MT. Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. Pharmacogenet Genomics. 2019 01; 29(1):18-22. PMID: 30489456; PMCID: PMC6358457.
      Citations: 8     Fields:    Translation:Humans
    66. McKenzie KA, El Ters M, Torres VE, Harris PC, Chapman AB, Mrug M, Rahbari-Oskoui FF, Bae KT, Landsittel DP, Bennett WM, Yu ASL, Mahnken JD. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol. 2018 12 27; 19(1):378. PMID: 30591038; PMCID: PMC6307167.
      Citations: 7     Fields:    Translation:Humans
    67. Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, Turner ST, Chapman AB, Gums JG, McDonough CW, Bailey KR, Beitelshees AL, Cooper-DeHoff RM, Scherer S, Boerwinkle E, Johnson JA. Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. Pharmacogenet Genomics. 2018 11; 28(11):251-255. PMID: 30289819; PMCID: PMC6262886.
      Citations: 5     Fields:    Translation:Humans
    68. Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470. PMID: 30228150; PMCID: PMC6171265.
      Citations: 83     Fields:    Translation:Humans
    69. Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA, Sá ACC. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genomics. 2018 Jun 20; 11(1):55. PMID: 29925376; PMCID: PMC6011347.
      Citations: 5     Fields:    Translation:Humans
    70. Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652. PMID: 28992127; PMCID: PMC5888998.
      Citations: 20     Fields:    Translation:Humans
    71. McDonough CW, Magvanjav O, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA, Sá ACC. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854. PMID: 29650764; PMCID: PMC5901893.
      Citations: 5     Fields:    Translation:Humans
    72. Rahbari-Oskoui FF, Chapman AB. Hypoxia-Inducible Factor 1a (HIF-1a), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease. Am J Nephrol. 2018; 47(4):228-230. PMID: 29597208.
      Citations:    Fields:    Translation:Humans
    73. Singh S, McDonough CW, Gong Y, Alghamdi WA, Arwood MJ, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira FA, Fredette NC, Shahin MH, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. J Am Heart Assoc. 2018 03 09; 7(6). PMID: 29523524; PMCID: PMC5907544.
      Citations: 10     Fields:    Translation:Humans
    74. Torres VE, Chapman AB, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD, TEMPO 4:4 Trial Investigators, Devuyst O. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 03 01; 33(3):477-489. PMID: 28379536; PMCID: PMC6019005.
      Citations: 50     Fields:    Translation:Humans
    75. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ß-Blockers. J Am Heart Assoc. 2018 02 24; 7(5). PMID: 29478026; PMCID: PMC5866313.
      Citations: 12     Fields:    Translation:Humans
    76. Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD. Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2018 May; 3(3):619-624. PMID: 29854969; PMCID: PMC5976807.
      Citations: 4     
    77. Eadon MT, Kanuri SH, Chapman AB. Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment. Expert Rev Precis Med Drug Dev. 2018; 3(1):33-47. PMID: 29888336; PMCID: PMC5990020.
      Citations: 8     
    78. Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE, HALT-PKD Trial Investigators. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis. 2018 05; 71(5):666-676. PMID: 29306517; PMCID: PMC5916329.
      Citations: 17     Fields:    Translation:Humans
    79. Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47. PMID: 29564978; PMCID: PMC6063360.
      Citations: 11     Fields:    Translation:Humans
    80. Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshees AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. J Am Heart Assoc. 2017 12 29; 7(1). PMID: 29288159; PMCID: PMC5778957.
      Citations: 12     Fields:    Translation:Humans
    81. Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018 03; 93(3):691-699. PMID: 29290310; PMCID: PMC5826779.
      Citations: 49     Fields:    Translation:Humans
    82. Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW. ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis. 2018 02; 71(2):294-296. PMID: 29203126; PMCID: PMC6267804.
      Citations: 2     Fields:    Translation:Humans
    83. Cho Y, Sautenet B, Rangan G, Craig JC, Ong ACM, Chapman A, Ahn C, Chen D, Coolican H, Kao JT, Gansevoort R, Perrone R, Harris T, Torres V, Pei Y, Kerr PG, Ryan J, Gutman T, Howell M, Ju A, Manera KE, Teixeira-Pinto A, Hamiwka LA, Tong A. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials. 2017 Nov 23; 18(1):560. PMID: 29169385; PMCID: PMC5701447.
      Citations: 6     Fields:    Translation:Humans
    84. Webb A, Gong Y, McDonough CW, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA, Sá ACC. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Sci Rep. 2017 11 22; 7(1):16068. PMID: 29167564; PMCID: PMC5700078.
      Citations: 3     Fields:    Translation:Humans
    85. Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Hays RD, Chapman AB, Perrone RD. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. Am J Kidney Dis. 2018 02; 71(2):225-235. PMID: 29150246.
      Citations: 23     Fields:    Translation:Humans
    86. Lanktree MB, Chapman AB. Autosomal dominant polycystic kidney disease. CMAJ. 2017 11 13; 189(45):E1396. PMID: 29133541; PMCID: PMC5687928.
      Citations: 2     Fields:    Translation:Humans
    87. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578. PMID: 29118087; PMCID: PMC5791072.
      Citations: 53     Fields:    Translation:Humans
    88. REPRISE Trial Investigators, Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 11 16; 377(20):1930-1942. PMID: 29105594.
      Citations: 225     Fields:    Translation:HumansCTClinical Trials
    89. Magvanjav O, Gong Y, McDonough CW, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Chapman AB. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11). PMID: 29097388; PMCID: PMC5721751.
      Citations: 8     Fields:    Translation:Humans
    90. Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE, HALT Investigators, Irazabal MV. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1857-1865. PMID: 27484667; PMCID: PMC5837227.
      Citations: 26     Fields:    Translation:Humans
    91. Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017 Dec; 13(12):750-768. PMID: 28989174.
      Citations: 31     Fields:    Translation:Humans
    92. Mehanna M, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Johnson JA, Turner ST, Cooper-DeHoff RM. Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1301-1308. PMID: 28940643; PMCID: PMC5722670.
      Citations: 7     Fields:    Translation:Humans
    93. Reddy BV, Chapman AB. A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 10 06; 12(10):1695-1698. PMID: 28784653; PMCID: PMC5628713.
      Citations: 4     Fields:    Translation:Humans
    94. Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD. Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4. Kidney Int Rep. 2017 Nov; 2(6):1132-1140. PMID: 29270521; PMCID: PMC5733681.
      Citations: 20     
    95. Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469. PMID: 28705885; PMCID: PMC5586583.
      Citations: 12     Fields:    Translation:HumansCells
    96. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD, TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2017 07 01; 32(7):1262. PMID: 28444221.
      Citations: 23     Fields:    
    97. Grantham JJ, Chapman AB, Blais J, Czerwiec FS, Gansevoort RT, Higashihara E, Krasa H, Zhou W, Ouyang J, Perrone RD, Torres VE, TEMPO 3:4 Investigators, Devuyst O. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Jun 01; 32(6):969-975. PMID: 27190355; PMCID: PMC5837351.
      Citations: 10     Fields:    Translation:Humans
    98. Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ, CRISP Investigators. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 11; 92(5):1206-1216. PMID: 28532709; PMCID: PMC5651185.
      Citations: 33     Fields:    Translation:Humans
    99. Pejchinovski M, Siwy J, Metzger J, Dakna M, Mischak H, Bae KT, Chapman AB, Kistler AD, Klein J, Jankowski V. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant. 2017 03 01; 32(3):487-497. PMID: 27382111.
      Citations: 14     Fields:    Translation:Humans
    100. Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017 May; 2(3):451-460. PMID: 29142972; PMCID: PMC5678607.
      Citations: 11     
    101. Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS. Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial. J Clin Pharmacol. 2017 07; 57(7):906-917. PMID: 28218410; PMCID: PMC5480307.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    102. Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2017; 45(3):257-266. PMID: 28166521; PMCID: PMC5497717.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    103. Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017 May; 2(3):442-450. PMID: 29142971; PMCID: PMC5678856.
      Citations: 52     
    104. Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE, HALT PKD Investigators. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120. PMID: 28460625; PMCID: PMC5688015.
      Citations: 21     Fields:    Translation:Humans
    105. Shahin MH, Webb A, Gong Y, Langaee T, McDonough CW, Riva A, Beitleshees AL, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Scherer SE, Sadee W, Cooper-DeHoff RM, Johnson JA, Sá AC. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1). PMID: 28115488; PMCID: PMC5298887.
      Citations: 8     Fields:    Translation:HumansCells
    106. Shen C, Landsittel D, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE, CRISP Investigators, Irazabal MV. Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. Am J Kidney Dis. 2017 03; 69(3):482-484. PMID: 28027795; PMCID: PMC5497695.
      Citations: 5     Fields:    Translation:Humans
    107. Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017 02; 91(2):493-500. PMID: 27993381; PMCID: PMC5237414.
      Citations: 44     Fields:    Translation:Humans
    108. Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol. 2017 May; 28(5):1592-1602. PMID: 27920153; PMCID: PMC5407721.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    109. Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT, TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease a. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. Am J Kidney Dis. 2017 Feb; 69(2):210-219. PMID: 27856088; PMCID: PMC5497700.
      Citations: 20     Fields:    Translation:Humans
    110. Salvi E, Wang Z, Rizzi F, Gong Y, McDonough CW, Padmanabhan S, Hiltunen TP, Lanzani C, Zaninello R, Chittani M, Bailey KR, Sarin AP, Barcella M, Melander O, Chapman AB, Manunta P, Kontula KK, Glorioso N, Cusi D, Dominiczak AF, Johnson JA, Barlassina C, Boerwinkle E, Cooper-DeHoff RM, Turner ST. Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension. 2017 01; 69(1):51-59. PMID: 27802415; PMCID: PMC5145728.
      Citations: 16     Fields:    Translation:Humans
    111. Kim Y, Bae SK, Cheng T, Tao C, Ge Y, Chapman AB, Torres VE, Yu AS, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT. Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease. Phys Med Biol. 2016 11 21; 61(22):7864-7880. PMID: 27779124; PMCID: PMC5244890.
      Citations: 6     Fields:    Translation:Humans
    112. Weng L, Gong Y, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman A, Boerwinkle E, Gums J, Beitelshees AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Metabolomics. 2016 10; 12(10). PMID: 28217401; PMCID: PMC5313050.
      Citations: 7     Fields:    
    113. Rocco MV, Chapman A, Chertow GM, Cohen D, Chen J, Cutler JA, Diamond MJ, Freedman BI, Hawfield A, Judd E, Killeen AA, Kirchner K, Lewis CE, Pajewski NM, Wall BM, Yee J, SPRINT Research Group. Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol. 2016; 44(2):130-40. PMID: 27513312; PMCID: PMC5096787.
      Citations: 8     Fields:    Translation:Humans
    114. Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, Higashihara E, Harris PC, Zhou W, Ouyang J, Czerwiec FS, Torres VE. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial. Kidney Int Rep. 2016 Nov; 1(4):213-220. PMID: 29142926; PMCID: PMC5678619.
      Citations: 24     
    115. de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics. 2016 08; 12(8). PMID: 28217400; PMCID: PMC5310671.
      Citations: 6     Fields:    
    116. Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshees AL, Garrett TJ, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, Johnson JA. A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension. 2016 09; 68(3):621-9. PMID: 27381900; PMCID: PMC4982802.
      Citations: 12     Fields:    Translation:HumansCells
    117. Gharaibeh KA, Turner ST, Hamadah AM, Chapman AB, Cooper-Dehoff RM, Johnson JA, Gums JG, Bailey KR, Schwartz GL. Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. Am J Hypertens. 2016 10; 29(10):1186-94. PMID: 27365079; PMCID: PMC5863787.
      Citations: 4     Fields:    Translation:Humans
    118. Mikolajczyk AE, Te HS, Chapman AB. Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease. Clin Gastroenterol Hepatol. 2017 01; 15(1):17-24. PMID: 27374006.
      Citations: 15     Fields:    Translation:Humans
    119. Porath B, Gainullin VG, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Le Meur Y, Torres VE, Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC, Cornec-Le Gall E, Herrero JI, Bañales JM, Vigneau C, Lavainne F, Audrézet MP, Ferec C. Mutations in GANAB, Encoding the Glucosidase IIa Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016 06 02; 98(6):1193-1207. PMID: 27259053; PMCID: PMC4908191.
      Citations: 174     Fields:    Translation:HumansCells
    120. Reddy BV, Chapman AB. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol. 2017 01; 32(1):31-42. PMID: 27034070.
      Citations: 18     Fields:    Translation:Humans
    121. Eadon MT, Chapman AB. A Physiologic Approach to the Pharmacogenomics of Hypertension. Adv Chronic Kidney Dis. 2016 Mar; 23(2):91-105. PMID: 26979148.
      Citations: 8     Fields:    Translation:HumansCells
    122. TEMPO 3:4 Trial Investigators, Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 05 06; 11(5):803-811. PMID: 26912543; PMCID: PMC4858477.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    123. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC, HALT PKD and CRISP Investigators. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84. PMID: 26823553; PMCID: PMC5004648.
      Citations: 93     Fields:    Translation:Humans
    124. Kim Y, Ge Y, Tao C, Zhu J, Chapman AB, Torres VE, Yu AS, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2016 Apr 07; 11(4):576-84. PMID: 26797708; PMCID: PMC4822671.
      Citations: 21     Fields:    Translation:Humans
    125. Gong Y, Wang Z, Beitelshees AL, McDonough CW, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to ß-Blockers in Hypertensive African Americans. Hypertension. 2016 Mar; 67(3):556-63. PMID: 26729753; PMCID: PMC4752391.
      Citations: 21     Fields:    Translation:Humans
    126. Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Grantham JJ, Higashihara E, Krasa HB, Ouyang J, Perrone RD, Torres VE, TEMPO 3:4 Investigators, Devuyst O. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2016 11; 31(11):1887-1894. PMID: 26681730; PMCID: PMC6367945.
      Citations: 28     Fields:    Translation:Humans
    127. Gong Y, McDonough CW, Beitelshees AL, El Rouby N, Hiltunen TP, O'Connell JR, Padmanabhan S, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Chapman AB, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens. 2015 Nov; 33(11):2278-85. PMID: 26425837; PMCID: PMC4788379.
      Citations: 22     Fields:    Translation:Humans
    128. Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC. Closeout of the HALT-PKD trials. Contemp Clin Trials. 2015 Sep; 44:48-55. PMID: 26231556; PMCID: PMC4732941.
      Citations: 1     Fields:    
    129. Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, Czerwiec FS, Dennis E, Kisler B, Kopko S, Krasa HB, LeRoy E, Castedo J, Schrier RW, Broadbent S. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct; 66(4):583-90. PMID: 26088508.
      Citations: 12     Fields:    Translation:Humans
    130. Reddy B, Chapman AB. Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy? Am J Kidney Dis. 2015 Jun; 65(6):811-3. PMID: 26003607.
      Citations: 3     Fields:    Translation:Humans
    131. Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, Fresu G, Citterio L, Braga D, Piras DA, Carpini SD, Velayutham D, Simonini M, Argiolas G, Pozzoli S, Troffa C, Glorioso V, Kontula KK, Hiltunen TP, Donner KM, Turner ST, Boerwinkle E, Chapman AB, Padmanabhan S, Dominiczak AF, Melander O, Johnson JA, Cooper-Dehoff RM, Gong Y, Rivera NV, Condorelli G, Trimarco B, Manunta P, Cusi D, Glorioso N, Barlassina C, Chittani M. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015 Jun; 33(6):1301-9. PMID: 25695618; PMCID: PMC4484731.
      Citations: 19     Fields:    Translation:Humans
    132. Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, Mrug M, Bae KT, Wu Z, Ge Y, Landslittel D, Gibbs P, O'Neill WC, Chapman AB, CRISP Investigators. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015 Jul; 88(1):146-51. PMID: 25830764; PMCID: PMC4490113.
      Citations: 57     Fields:    Translation:Humans
    133. Chapman AB, Devuyst O, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Schrier RW, Torres VE, Watnick T, Wheeler DC, Conference Participants, Eckardt KU, Pirson Y, Torra R. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul; 88(1):17-27. PMID: 25786098; PMCID: PMC4913350.
      Citations: 218     Fields:    Translation:Humans
    134. Knight T, Schaefer C, Krasa H, Oberdhan D, Chapman A, Perrone RD. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. Clinicoecon Outcomes Res. 2015; 7:123-32. PMID: 25759590; PMCID: PMC4345925.
      Citations: 13     
    135. Weng L, Quinlivan E, Gong Y, Beitelshees AL, Shahin MH, Turner ST, Chapman AB, Gums JG, Johnson JA, Frye RF, Garrett TJ, Cooper-DeHoff RM. Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metab Syndr Relat Disord. 2015 Jun; 13(5):195-202. PMID: 25664967; PMCID: PMC4519105.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    136. Langaee T, Hamadeh I, Chapman AB, Gums JG, Johnson JA. A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication. PLoS One. 2015; 10(1):e0113808. PMID: 25625348; PMCID: PMC4308104.
      Citations: 17     Fields:    Translation:Humans
    137. Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, Gums JG, Gong Y, Cooper-DeHoff RM, Frau F, Glorioso V, Zaninello R, Salvi E, Glorioso N, Boerwinkle E, Turner ST, Johnson JA, Kontula KK. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26; 4(1):e001521. PMID: 25622599; PMCID: PMC4330076.
      Citations: 40     Fields:    Translation:Humans
    138. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD, HALT-PKD Trial Investigators. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76. PMID: 25399731; PMCID: PMC4284824.
      Citations: 121     Fields:    Translation:Humans
    139. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB, HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66. PMID: 25399733; PMCID: PMC4343258.
      Citations: 194     Fields:    Translation:Humans
    140. Fontana V, McDonough CW, Gong Y, El Rouby NM, Taylor KD, Chen YD, Gums JG, Chapman AB, Turner ST, Pepine CJ, Johnson JA, Cooper-DeHoff RM, Sá AC. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014 Nov 10; 3(6):e001398. PMID: 25385345; PMCID: PMC4338734.
      Citations: 20     Fields:    Translation:Humans
    141. Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Beitelshees AL, Chapman A, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Johnson JA. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014 Nov; 34(11):1132-40. PMID: 25202885; PMCID: PMC4227953.
      Citations: 5     Fields:    Translation:Humans
    142. Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):155-64.e6. PMID: 25111236; PMCID: PMC4267913.
      Citations: 51     Fields:    Translation:Humans
    143. Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, CRISP Investigators, Irazabal MV. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan; 26(1):160-72. PMID: 24904092; PMCID: PMC4279733.
      Citations: 246     Fields:    Translation:Humans
    144. Cooper-Dehoff RM, Hou W, Weng L, Baillie RA, Beitelshees AL, Gong Y, Shahin MH, Turner ST, Chapman A, Gums JG, Boyle SH, Zhu H, Wikoff WR, Boerwinkle E, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Is diabetes mellitus-linked amino acid signature associated with ß-blocker-induced impaired fasting glucose? Circ Cardiovasc Genet. 2014 Apr; 7(2):199-205. PMID: 24627569; PMCID: PMC4050976.
      Citations: 16     Fields:    Translation:Humans
    145. Bae KT, Sun H, Lee JG, Bae K, Wang J, Tao C, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease. Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol. 2014; 39(3):210-7. PMID: 24576800; PMCID: PMC4020571.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    146. Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014 Dec; 29(12):2194-201. PMID: 24463189.
      Citations: 27     Fields:    Translation:Humans
    147. Rosenwasser RF, Shah NK, Smith SM, Wen X, Gong Y, Gums JG, Nichols WW, Chapman AB, Boerwinkle E, Johnson J, Epstein B. Baseline predictors of central aortic blood pressure: a PEAR substudy. J Am Soc Hypertens. 2014 Mar; 8(3):152-8. PMID: 24629400; PMCID: PMC3959656.
      Citations: 8     Fields:    Translation:Humans
    148. Mittal A, Mittal P, Chapman A, Rahbari-Oskoui F. Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 Feb; 9(2):406-15. PMID: 24370765; PMCID: PMC3913246.
      Citations: 22     Fields:    Translation:Humans
    149. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW, HALT-PKD Study. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014 Feb; 63(2):214-26. PMID: 24183837; PMCID: PMC4075014.
      Citations: 50     Fields:    Translation:Humans
    150. Gong Y, McDonough CW, Beitelshees AL, Karnes JH, O'Connell JR, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA, Cooper-DeHoff RM. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014 Feb; 34(2):123-30. PMID: 24122840; PMCID: PMC3945213.
      Citations: 6     Fields:    Translation:Humans
    151. McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, Shahin MH, Buford TW, El Rouby NM, Langaee TY, Gums JG, Chapman AB, Cooper-DeHoff RM, Turner ST, Gong Y, Johnson JA, Sá AC. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013; 8(10):e76984. PMID: 24116192; PMCID: PMC3792156.
      Citations: 7     Fields:    Translation:Humans
    152. Bae KT, Tao C, Wang J, Kaya D, Wu Z, Bae JT, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol. 2013; 38(4):333-41. PMID: 24107679; PMCID: PMC3863613.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    153. Chapman AB, Cotsonis G, Parekh V, Schwartz GL, Gong Y, Bailey KR, Turner ST, Gums JG, Beitelshees AL, Cooper-DeHoff R, Boerwinkle E, Johnson JA. Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens. 2014 Apr; 27(4):546-54. PMID: 23886594; PMCID: PMC3958600.
      Citations: 3     Fields:    Translation:Humans
    154. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Manunta P, Kontula K, Dominiczak AF, Cooper-DeHoff RM, Johnson JA, Wahlstrand B. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013 Aug; 62(2):391-7. PMID: 23753411; PMCID: PMC3780966.
      Citations: 54     Fields:    Translation:HumansCells
    155. Schwartz GL, Bailey K, Chapman AB, Boerwinkle E, Turner ST. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013 Aug; 26(8):957-64. PMID: 23591988; PMCID: PMC3816320.
      Citations: 13     Fields:    Translation:Humans
    156. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshees AL, Boerwinkle E, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013 Apr; 31(4):698-704. PMID: 23353631; PMCID: PMC3756535.
      Citations: 38     Fields:    Translation:Humans
    157. Bae K, Park B, Sun H, Wang J, Tao C, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2013 Jul; 8(7):1089-97. PMID: 23520042; PMCID: PMC3700699.
      Citations: 20     Fields:    Translation:Humans
    158. Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, Cooper-Dehoff RM, Beitelshees AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R, Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013; 8(3):e57639. PMID: 23536766; PMCID: PMC3594230.
      Citations: 38     Fields:    Translation:Humans
    159. Le MT, Lobmeyer MT, Campbell M, Cheng J, Wang Z, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Gong Y, Johnson RJ, Johnson JA. Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals. PLoS One. 2013; 8(1):e52062. PMID: 23341889; PMCID: PMC3544854.
      Citations: 7     Fields:    Translation:Humans
    160. Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Mischak H, Chapman AB, Kistler AD, Wüthrich RP. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One. 2013; 8(1):e53016. PMID: 23326375; PMCID: PMC3542378.
      Citations: 31     Fields:    Translation:Humans
    161. Chai HS, Chapman AB, Boerwinkle E. Response to genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2013 Jan; 61(1):e6. PMID: 23362515.
      Citations:    Fields:    Translation:Humans
    162. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20; 367(25):2407-18. PMID: 23121377; PMCID: PMC3760207.
      Citations: 651     Fields:    Translation:HumansCTClinical Trials
    163. Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, Beitelshees AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012 Dec; 5(6):686-91. PMID: 23087401; PMCID: PMC3529147.
      Citations: 27     Fields:    Translation:Humans
    164. Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, Beitelshees AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64. PMID: 22949529; PMCID: PMC3462355.
      Citations: 35     Fields:    Translation:Humans
    165. Shafiu M, Johnson RJ, Turner ST, Langaee T, Gong Y, Chapman AB, Gums JG, Johnson JA. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012; 35(6):477-82. PMID: 22688828; PMCID: PMC3480975.
      Citations: 19     Fields:    Translation:Humans
    166. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012 Jun; 59(6):1204-11. PMID: 22566498; PMCID: PMC3530397.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    167. Chapman AB. The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease. Kidney Int. 2012 May; 81(9):814-5. PMID: 22499140; PMCID: PMC3489014.
      Citations: 6     Fields:    Translation:Humans
    168. Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-Dehoff RM, Beitelshees AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med. 2012 Mar 22; 10:56. PMID: 22440088; PMCID: PMC3320544.
      Citations: 17     Fields:    Translation:HumansCells
    169. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-Dehoff RM, Boerwinkle E, Johnson JA, Bailey KR. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med. 2012 Mar 13; 10:47. PMID: 22413836; PMCID: PMC3342146.
      Citations: 19     Fields:    Translation:Humans
    170. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012 Mar; 7(3):479-86. PMID: 22344503; PMCID: PMC3302672.
      Citations: 172     Fields:    Translation:Humans
    171. Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, Zeltner R, Tian X, Grantham JJ, Somlo S. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012 Apr; 81(8):784-90. PMID: 22258321; PMCID: PMC3319327.
      Citations: 32     Fields:    Translation:HumansAnimals
    172. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW, HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar; 81(6):577-85. PMID: 22205355; PMCID: PMC3580956.
      Citations: 41     Fields:    Translation:Humans
    173. Smith SM, Gong Y, Turner ST, Cooper-DeHoff RM, Beitelshees AL, Chapman AB, Boerwinkle E, Bailey K, Johnson JA, Gums JG. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens. 2012 Mar; 25(3):359-65. PMID: 22089105; PMCID: PMC3288583.
      Citations: 9     Fields:    Translation:Humans
    174. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2499-507. PMID: 21903984; PMCID: PMC3359559.
      Citations: 68     Fields:    Translation:Humans
    175. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT, HALT PKD Study Group, Meyers CM. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2508-15. PMID: 21903983; PMCID: PMC3186455.
      Citations: 23     Fields:    Translation:Humans
    176. Desai T, Stankeyeva D, Chapman A, Bailey J. Nephrology fellows show consistent use of, and improved knowledge from, a nephrologist-programmed teaching instrument. J Nephrol. 2011 May-Jun; 24(3):345-50. PMID: 20954135.
      Citations: 3     Fields:    Translation:Humans
    177. Chapman AB, Wei W. Imaging approaches to patients with polycystic kidney disease. Semin Nephrol. 2011 May; 31(3):237-44. PMID: 21784272; PMCID: PMC3143364.
      Citations: 23     Fields:    Translation:Humans
    178. Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 May; 57(5):692-9. PMID: 21333426.
      Citations: 58     Fields:    Translation:Humans
    179. Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, Cooper-DeHoff RM, Beitelshees AL, Bailey KR, Boerwinkle E, Pepine CJ, Johnson JA. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011 Jan; 21(1):42-9. PMID: 21127457; PMCID: PMC3028503.
      Citations: 35     Fields:    Translation:Humans
    180. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, Wetzel LH, Martin D, Lockhart ME, Bennett WM, Moxey-Mims M, Abebe KZ, Lin Y, Bost JE, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Mar; 6(3):640-7. PMID: 21088290; PMCID: PMC3082424.
      Citations: 68     Fields:    Translation:Humans
    181. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010 Sep; 23(9):1014-22. PMID: 20725057; PMCID: PMC2941699.
      Citations: 36     Fields:    Translation:Humans
    182. Duarte JD, Lobmeyer MT, Wang Z, Chapman AB, Gums JG, Langaee TY, Boerwinkle E, Turner ST, Johnson JA. Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010 Aug; 20(8):516-9. PMID: 20555294; PMCID: PMC2922977.
      Citations: 8     Fields:    Translation:Humans
    183. Zhou J, Ouyang X, Cui X, Schoeb TR, Smythies LE, Johnson MR, Guay-Woodford LM, Chapman AB, Mrug M. Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int. 2010 Sep; 78(6):550-60. PMID: 20555320; PMCID: PMC3422025.
      Citations: 22     Fields:    Translation:HumansAnimals
    184. Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol. 2010 Jul; 5(7):1312-29. PMID: 20498248; PMCID: PMC5619657.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    185. Dambreville S, Chapman AB, Torres VE, King BF, Wallin AK, Frakes DH, Yoganathan AP, Wijayawardana SR, Easley K, Bae KT, Brummer ME, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects. Magn Reson Med. 2010 Apr; 63(4):940-50. PMID: 20373395; PMCID: PMC3760266.
      Citations: 10     Fields:    Translation:Humans
    186. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010 Mar; 17(2):153-63. PMID: 20219618; PMCID: PMC2845913.
      Citations: 70     Fields:    Translation:Humans
    187. Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010 Feb; 31(2):440-6. PMID: 20099361; PMCID: PMC3698801.
      Citations: 26     Fields:    Translation:HumansCells
    188. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2010 Jan; 5(1):102-9. PMID: 20089507; PMCID: PMC2801653.
      Citations: 65     Fields:    Translation:Humans
    189. Beitelshees AL, Gong Y, Bailey KR, Turner ST, Chapman AB, Schwartz GL, Gums JG, Boerwinkle E, Johnson JA. Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):14-21. PMID: 20047624; PMCID: PMC2841560.
      Citations: 5     Fields:    Translation:Humans
    190. Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010 Jan; 55(1):61-8. PMID: 19917874; PMCID: PMC2811061.
      Citations: 33     Fields:    Translation:Humans
    191. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009 Oct; 29(10):1157-65. PMID: 19792989; PMCID: PMC2777624.
      Citations: 17     Fields:    Translation:Humans
    192. Barbalic M, Schwartz GL, Chapman AB, Turner ST, Boerwinkle E. Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study. Physiol Genomics. 2009 Sep 09; 39(1):56-60. PMID: 19584173; PMCID: PMC2747342.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    193. Chapman A. Polycystic kidney disease: The cadence of kidney growth in ADPKD. Nat Rev Nephrol. 2009 Jun; 5(6):311-2. PMID: 19474826.
      Citations:    Fields:    Translation:Humans
    194. Chapman AB, Guay-Woodford LM. Renal volume in children with ADPKD: size matters. Clin J Am Soc Nephrol. 2009 Apr; 4(4):698-9. PMID: 19339418.
      Citations: 5     Fields:    Translation:Humans
    195. Bae KT, Tao C, Zhu F, Bost JE, Chapman AB, Grantham JJ, Torres VE, Guay-Woodford LM, Meyers CM, Bennett WM, Consortium for Radiologic Imaging Studies Polycystic Kidney Disease. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol. 2009 Apr; 4(4):719-25. PMID: 19339416; PMCID: PMC2666436.
      Citations: 34     Fields:    Translation:Humans
    196. Rizk D, Jurkovitz C, Veledar E, Bagby S, Baumgarten DA, Rahbari-Oskoui F, Steinman T, Chapman AB. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009 Mar; 4(3):560-6. PMID: 19261830; PMCID: PMC2653655.
      Citations: 31     Fields:    Translation:Humans
    197. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, Gums J, Curry RW, Gong Y, Beitelshees AL, Schwartz G, Turner ST. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009 Mar; 157(3):442-9. PMID: 19249413; PMCID: PMC2671287.
      Citations: 82     Fields:    Translation:Humans
    198. Chapman AB, Guay-Woodford LM. Nurturing passion in a time of academic climate change: the modern-day challenge of junior faculty development. Clin J Am Soc Nephrol. 2008 Nov; 3(6):1878-83. PMID: 18945997; PMCID: PMC4653761.
      Citations: 12     Fields:    Translation:Humans
    199. Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, Rangel LJ, Aspinwall R, Niaudet WP, Ozen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Sampson JR, Dawson BD, Harris PC, CRISP Consortium. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008 Dec; 74(11):1468-79. PMID: 18818683; PMCID: PMC2756756.
      Citations: 58     Fields:    Translation:Humans
    200. Fridley BL, Turner ST, Chapman A, Rodin A, Boerwinkle E, Bailey K. Reproducibility of Genotypes as Measured by the Affymetrix GeneChip® 100K Human Mapping Array Set. Comput Stat Data Anal. 2008 Aug 15; 52(12):5367-5374. PMID: 19684844; PMCID: PMC2597860.
      Citations: 3     
    201. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, Sicotte H, Kocher JP, Boerwinkle E, Rodin AS. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008 Aug; 52(2):359-65. PMID: 18591461; PMCID: PMC2692710.
      Citations: 55     Fields:    Translation:HumansCells
    202. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1197-204. PMID: 18579674.
      Citations: 44     Fields:    Translation:Humans
    203. Rizk D, Chapman A. Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. Pediatr Nephrol. 2008 Jul; 23(7):1029-36. PMID: 18259779.
      Citations: 14     Fields:    Translation:Humans
    204. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008 Jan; 21(1):61-6. PMID: 18091745.
      Citations: 27     Fields:    Translation:Humans
    205. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC, CRISP Consortium. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007 Jul; 18(7):2143-60. PMID: 17582161.
      Citations: 189     Fields:    Translation:Humans
    206. Chapman AB. Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol. 2007 May; 18(5):1399-407. PMID: 17429048.
      Citations: 26     Fields:    Translation:Humans
    207. Levin A, Linas S, Luft FC, Chapman AB, Textor S, ASN HTN Advisory Group. Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on Hypertension. Am J Nephrol. 2007; 27(2):212-20. PMID: 17377375.
      Citations: 14     Fields:    Translation:Humans
    208. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2007 Jan; 2(1):112-20. PMID: 17699395.
      Citations: 61     Fields:    Translation:Humans
    209. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006 Nov; 17(11):3013-9. PMID: 17035604.
      Citations: 116     Fields:    Translation:Humans
    210. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP, CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med. 2006 May 18; 354(20):2122-30. PMID: 16707749.
      Citations: 323     Fields:    Translation:Humans
    211. Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP, CRISP Consortium. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006 Mar; 17(3):854-62. PMID: 16452494.
      Citations: 30     Fields:    Translation:Humans
    212. O'Neill WC, Robbin ML, Bae KT, Grantham JJ, Chapman AB, Guay-Woodford LM, Torres VE, King BF, Wetzel LH, Thompson PA, Miller JP. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis. 2005 Dec; 46(6):1058-64. PMID: 16310571.
      Citations: 53     Fields:    Translation:Humans
    213. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006 Jan; 1(1):64-9. PMID: 17699192.
      Citations: 132     Fields:    Translation:Humans
    214. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006 Jan; 1(1):148-57. PMID: 17699202.
      Citations: 115     Fields:    Translation:Humans
    215. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005 Oct; 46(4):758-65. PMID: 16172412.
      Citations: 26     Fields:    Translation:Humans
    216. Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens. 2005 Aug; 18(8):1077-83. PMID: 16109321.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    217. Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet Genomics. 2005 May; 15(5):287-93. PMID: 15864129.
      Citations: 10     Fields:    Translation:Humans
    218. Finkielman JD, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens. 2005 Mar; 18(3):398-402. PMID: 15797660.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    219. Rizk D, Chapman AB. Cystic and inherited kidney diseases. Am J Kidney Dis. 2003 Dec; 42(6):1305-17. PMID: 14655206.
      Citations: 18     Fields:    Translation:Humans
    220. King BF, Torres VE, Brummer ME, Chapman AB, Bae KT, Glockner JF, Arya K, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Dec; 64(6):2214-21. PMID: 14633145.
      Citations: 37     Fields:    Translation:Humans
    221. Schrier RW, Johnson AM, McFann K, Chapman AB. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Nov; 64(5):1792-9. PMID: 14531813.
      Citations: 26     Fields:    Translation:Humans
    222. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003 Oct; 16(10):834-9. PMID: 14553962.
      Citations: 26     Fields:    Translation:Humans
    223. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003 Sep; 64(3):1035-45. PMID: 12911554.
      Citations: 159     Fields:    Translation:Humans
    224. Belz MM, Fick-Brosnahan GM, Hughes RL, Rubinstein D, Chapman AB, Johnson AM, McFann KK, Kaehny WD, Gabow PA. Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 May; 63(5):1824-30. PMID: 12675859.
      Citations: 16     Fields:    Translation:Humans
    225. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E, Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int. 2002 Nov; 62(5):1718-23. PMID: 12371972.
      Citations: 19     Fields:    Translation:Humans
    226. Finkielman JD, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST, Finkielman JD, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Reproducibility of blood pressure response to hydrochlorothiazide. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):408-12. PMID: 12461303; PMCID: PMC8101852.
      Citations: 4     Fields:    Translation:Humans
    227. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002 Nov; 48(11):1919-23. PMID: 12406976.
      Citations: 12     Fields:    Translation:Humans
    228. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9. PMID: 12089368.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    229. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002 Mar; 61(3):1047-55. PMID: 11849460.
      Citations: 49     Fields:    Translation:Humans
    Chapman's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (532)
    Explore
    _
    Co-Authors (10)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _